A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma

Sponsor
Ruijin Hospital
Study ID
NCT05852028
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Selinexor — DRUG
    this is a real-world. Patients who use selinexor-based regimens in lymphoma will be followed up without interfering with the choice of treatment options for patients

Study Details

This study aims to observe and explore the efficacy and safety of selinexor-based regimen in patients with Non-Hodgkin lymphoma

Key Dates

Start date
Dec 15, 2022
Status verified
May 2023
Primary completion
Oct 10, 2024
Completion
Oct 18, 2025

Study Design

Enrollment
250 participants (estimated)

Arms

  • Arm: selinexor-based regimens
    This study is a real-world study to explore the safety and efficacy of selinexor-based therapy in patients with lymphoma. It is planned to enroll 250 patients with lymphoma, including 150 patients with diffuse large B-cell lymphoma and 100 patients with peripheral T and NK/T-cell lymphoma.

Primary Outcome Measure

Objective response rate(ORR) [ Time Frame: throughout the study, an average of 1 year ]

Central Contacts

Related Studies